Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity.
Rosás-Umbert M, Gunst JD, Pahus MH, Olesen R, Schleimann M, Denton PW, Ramos V, Ward A, Kinloch NN, Copertino DC, Escribà T, Llano A, Brumme ZL, Brad Jones R, Mothe B, Brander C, Fox J, Nussenzweig MC, Fidler S, Caskey M, Tolstrup M, Søgaard OS.
Rosás-Umbert M, et al. Among authors: sogaard os.
Nat Commun. 2022 Oct 29;13(1):6473. doi: 10.1038/s41467-022-34171-2.
Nat Commun. 2022.
PMID: 36309514
Free PMC article.